Fingerprint
Dive into the research topics of 'A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: A trial of the ECOG-ACRIN cancer research group (E1908)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically